 |
|
|
 |
|
|
|
10-12 April 2017
Dubai | UAE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Saturday, 15 April
2017 | ArabMedicare.com | Staff Reporter
|
|
|
| |
|
Herbert Pohle, Boehringer
Ingelheim’s
Head of Animal health META |
Boehringer Ingelheim driving
industry leadership in animal
health after acquiring Merial |
|
| |
(Dubai) -
Three
months after acquiring
animal health leader Merial
in a strategic transaction
with Sanofi, Boehringer
Ingelheim revealed its
ambition to compete for
industry leadership
worldwide in animal health.
Boehringer Ingelheim's
management recently
discussed the importance of
its animal health business
and its long-term growth
potential at a briefing
event that took place in
Ingelheim, Germany.
Following a positive year
for the animal health
business in 2016 with net
sales increasing by 8.5
percent in currency adjusted
terms to 1.46 billion euros,
Boehringer Ingelheim
finalized the acquisition of
Merial on 1 January 2017.
With the combination of
these two leading and highly
complementary businesses,
animal health has been
identified as a strategic
long-term development
priority for the company.
Joachim Hasenmaier, Head of
Boehringer Ingelheim's
Animal Health Business Unit
and member of the Boehringer
Ingelheim board of managing
directors said, "Acquiring
Merial immediately positions
us to be increasingly
competitive in a high-growth
sector that is in a
consolidation phase. By
combining two dynamic
companies that share the
same long-term strategic
vision, we are delivering a
larger and more innovative
portfolio of products and
services to prevent disease
and improve the health and
productivity of animals
around the world. We want to
actively help shape the
animal health industry by
combining our forces, one
with the power of two."
Moreover, Herbert Pohle,
Boehringer Ingelheim's Head
of Animal health META also
noted, "Animal health is one
of the key drivers to
sustainable human health. In
large areas across the
region, the animal health
sector is of strategic
importance as it directly
links to our daily lives and
overall nutrition. We remain
committed to strengthening
the Boehringer Ingelheim
Animal Health Business Unit
across the region by driving
market leadership,
leveraging innovation and
providing customer service
excellence."
Pohle further added, "We
will continue strengthening
our relationship with our
partners, and work with them
to
help
drive best practices, and
further develop
problem-solving health
solutions that maximize
productivity."
Between now and 2030, the
latest forecasts predict the
animal health market will
double, reaching 53 billion
euros. This growth will be
driven by three major
trends: increasing demand
for animal meat in
connection with changing
demographics, increasing
demand and diversification
in the pet market, and
increasing health threats
due to the spread of
infectious diseases from
animals (avian influenza,
foot-and-mouth disease,
etc.).
The new
Boehringer Ingelheim animal
health business is now the
second largest company in
the global animal health
market, and is one of the top
provider worldwide of
parasiticides and vaccines
for animals
and pets. The combined
company's portfolio spans
across a wide range of
products for cattle, pets,
poultry, swine, equine and
other
veterinary public health
categories.
"We see an important
opportunity to capitalize on
the evolving trends and
critical needs to prevent
disease and manage the
health of animals
worldwide," added Hasenmaier.
"We intend to do so by
ensuring a smooth
integration of our
businesses; extending our
leadership in vaccination
and parasite control
programs, and focusing on
pet care solutions. It is
our ambition to develop new
products and solutions that
address unmet customer needs
with an industry leading R&D
investment up to 10%."
Pohle further pointed out to
that, "Preventive
vaccination is one approach
to controlling any diseases.
The region has applied a lot
of advances in this area and
our commitment is to support
in the investment in a
healthier and more robust
animal health sector which
in return would reflect in
stronger communities."
The combined animal health
business will in the future
represent more than 25
percent of Boehringer
Ingelheim's total revenue
and employ more than 10,000
people. Boehringer Ingelheim
expects animal health net
sales to more than double in
2017 in comparison to the
previous year due to the
Merial integration.
PRINT
THIS ARTICLE
|
|
|
|
|
|
|
|
